Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Healthcare Analyst

Wilfred Yuen

Equity Bottom-Up

Sino Biopharmaceutical / Equity Bottom-Up

<ul>
<li>Today SBP (1177.HK) announced two deals today: 1) licensing out ex-China rights of PDE3/4 inhibitor TQC3721 to AstraZeneca; 2) obtained China sales right for two respiratory drugs from GSK</li>
<li>SBP will receive USD200m upfront from AstraZeneca (mgmt expects majority to recognise in 2H26); SBP expects c.RMB1bn incremental revenue from GSK's Trelegy Ellipta and Anoro Ellipta in China.</li>
<li>On future BD deals, SBP highlights key data readouts and registration study initiations in 2H26, as well as key upcoming IND filings. See below tables for details.</li>
</ul>


Today SBP (1177.HK) announced two deals today: 1) licensing out ex-China rights of PDE3/4 inhibitor TQC3721 to AstraZeneca; 2) obtained China sales right for two respiratory drugs from GSK
SBP will receive USD200m upfront from AstraZeneca (mgmt expects majority to recognise in 2H26); SBP expects c.RMB1bn incremental revenue from GSK's Trelegy Ellipta and Anoro Ellipta in China.
On future BD deals, SBP highlights key data readouts and registration study initiations in 2H26, as well as key upcoming IND filings. See below tables for details.


Sino Biopharm (1177.HK): Call Takeaways on BD Deals with AstraZeneca and GSK

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>
<a href="https://smartkarma.com/entities/astrazeneca-plc-f0b2cf64-9cf8-4611-9b01-8dbb89944a0c">AstraZeneca </a>is poised for significant growth, driven by its robust oncology portfolio and a deep, late-stage pipeline with over 20 potential new medicine launches by 2030, targeting an ambitious revenue goal of $80 billion.</li>
  <li>The company's strategic focus on high-growth specialty areas like oncology and rare diseases (through the Alexion acquisition) provides a strong competitive moat, supported by heavy R&amp;D investment and a leading position in emerging markets, particularly China.</li>
  <li>Key risks include increasing drug pricing pressure from governments and payers, the ever-present threat of clinical trial failures for its pipeline assets, and future patent expirations on key blockbuster drugs which could open the door to generic competition.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  
AstraZeneca is poised for significant growth, driven by its robust oncology portfolio and a deep, late-stage pipeline with over 20 potential new medicine launches by 2030, targeting an ambitious revenue goal of $80 billion.
  The company's strategic focus on high-growth specialty areas like oncology and rare diseases (through the Alexion acquisition) provides a strong competitive moat, supported by heavy R&amp;D investment and a leading position in emerging markets, particularly China.
  Key risks include increasing drug pricing pressure from governments and payers, the ever-present threat of clinical trial failures for its pipeline assets, and future patent expirations on key blockbuster drugs which could open the door to generic competition.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>AstraZeneca reported an 8% increase in total revenue for the first quarter of 2026, driven by strong demand for its innovative medicines and robust growth across oncology and rare disease sectors.</li><li>Operating profit rose by 12%, attributed to operating leverage, while core earnings per share advanced 5%, albeit impacted by a low prior period tax rate.</li><li>The company secured 14 new approvals since the end of 2025 and continues broad investment in R&D, including transformative technologies such as cell therapies and T cell engagers.</li></ul>

AstraZeneca reported an 8% increase in total revenue for the first quarter of 2026, driven by strong demand for its innovative medicines and robust growth across oncology and rare disease sectors.Operating profit rose by 12%, attributed to operating leverage, while core earnings per share advanced 5%, albeit impacted by a low prior period tax rate.The company secured 14 new approvals since the end of 2025 and continues broad investment in R&D, including transformative technologies such as cell therapies and T cell engagers.

AstraZeneca: Why Datroway’s Oncology Trials Could Become A Major Inflection Point For Future Growth!

<ul><li>AstraZeneca has steadily built one of the most diversified oncology portfolios in the pharmaceutical industry, and a single drug increasingly sits at the center of that strategy: Imfinzi.</li><li>Originally launched in 2017 as an immunotherapy for lung cancer, the drug has gradually expanded into multiple tumor types, including bladder, liver, biliary tract, and endometrial cancers.</li><li>The latest milestone came with regulatory approval in Europe allowing Imfinzi to be used in combination with chemotherapy for early-stage gastric and gastroesophageal cancers, marking yet another step in the drug’s expanding clinical footprint.</li></ul>

AstraZeneca has steadily built one of the most diversified oncology portfolios in the pharmaceutical industry, and a single drug increasingly sits at the center of that strategy: Imfinzi.Originally launched in 2017 as an immunotherapy for lung cancer, the drug has gradually expanded into multiple tumor types, including bladder, liver, biliary tract, and endometrial cancers.The latest milestone came with regulatory approval in Europe allowing Imfinzi to be used in combination with chemotherapy for early-stage gastric and gastroesophageal cancers, marking yet another step in the drug’s expanding clinical footprint.

AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer

United Kingdom

AstraZeneca is a Swedish-British multinational pharmaceutical and biotechnology company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was formed in 1999 through the merger of Astra AB and Zeneca Group PLC and is headquartered in Cambridge, UK.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

AstraZeneca (AZN LN)

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Sino Biopharm (1177.HK): Call Takeaways on BD Deals with AstraZeneca and GSK

SBP to receive USD200m upfront from AZ for license-out PDE3/4. SBP obtained sales rights of 2 GSK drugs (with c.RMB1bn revenue). SBP highlights its...

Wilfred Yuen

Primer: AstraZeneca (AZN SS) - May 2026

AstraZeneca is poised for significant growth, driven by its robust oncology portfolio and a deep, late-stage pipeline with over 20 potential...

αSK Primers

AstraZeneca: Why Datroway’s Oncology Trials Could Become A Major Inflection Point For Future Growth!

AstraZeneca reported an 8% increase in total revenue for the first quarter of 2026, driven by strong demand for its innovative medicines and...

Baptista Research

AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer

AstraZeneca has steadily built one of the most diversified oncology portfolios in the pharmaceutical industry, and a single drug increasingly sits...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)